The excitement around new systemic therapies has already created a "Wild West" environment where patient and surgeon motivation for cystectomy has plummeted. This cultural shift is outpacing prospective data, raising concerns that patients are making major decisions outside of rigorous clinical trials.

While bladder preservation is a key goal, there is an unavoidable risk. Forgoing definitive local treatment like surgery means a subset of patients will not be cured by systemic therapy alone and will miss their opportunity for a potentially curative operation, a crucial ethical consideration.

The chemoradiation control arm in SUNRISE 2 performed so well (e.g., 95% 1-year overall survival) that it challenges the long-held belief that surgery is unequivocally superior. This result, alongside other recent studies, suggests chemoradiation should be considered a potent standard-of-care contender for bladder preservation in appropriately selected patients.

While new systemic agents dominate MIBC discussions, chemo-radiation remains a critical treatment, especially for patients unsuitable for radical cystectomy due to age or comorbidities. For these individuals, it offers a potentially curative, bladder-preserving alternative that avoids the high risks and sequelae of major surgery.

A notable trend is patients achieving a strong response to neoadjuvant therapy and then refusing definitive local treatment like cystectomy. Experts caution against this "off-study" approach, as it deviates from the curative backbone of care and undermines the ability to build an evidence base for bladder preservation strategies.

The SURE-01 trial's data suggests non-luminal subtypes and low TOP1 expression are linked to better outcomes with sacituzumab govitecan. This finding points toward a future where molecular profiling, not just treatment ineligibility, could guide personalized neoadjuvant therapy selection for patients.

For muscle-invasive bladder cancer patients achieving a complete response to neoadjuvant therapy, a barrier to forgoing bladder removal is local relapse risk. Adding intravesical BCG could prevent these recurrences, making bladder preservation a more viable long-term strategy for these patients.

The success of new treatments like immunotherapy and ADCs leads to more patients achieving a deep response. This high efficacy makes patients question the necessity of a radical cystectomy, a life-altering surgery, creating an urgent need for data-driven, bladder-sparing protocols.

With pathologic complete response rates approaching 67% in patients completing neoadjuvant EV-Pembro, a majority of cystectomies are now removing cancer-free bladders. This creates an ethical and clinical imperative to rapidly launch prospective trials to validate bladder preservation strategies and avoid overtreatment.